These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 28576350)

  • 1. Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial.
    Cooper RE; Williams E; Seegobin S; Tye C; Kuntsi J; Asherson P
    Eur Neuropsychopharmacol; 2017 Aug; 27(8):795-808. PubMed ID: 28576350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study.
    Weisler RH; Greenbaum M; Arnold V; Yu M; Yan B; Jaffee M; Robertson B
    CNS Drugs; 2017 Aug; 31(8):685-697. PubMed ID: 28712074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
    Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
    J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurofeedback, sham neurofeedback, and cognitive-behavioural group therapy in adults with attention-deficit hyperactivity disorder: a triple-blind, randomised, controlled trial.
    Schönenberg M; Wiedemann E; Schneidt A; Scheeff J; Logemann A; Keune PM; Hautzinger M
    Lancet Psychiatry; 2017 Sep; 4(9):673-684. PubMed ID: 28803030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Wilens TE; Robertson B; Sikirica V; Harper L; Young JL; Bloomfield R; Lyne A; Rynkowski G; Cutler AJ
    J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):916-25.e2. PubMed ID: 26506582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
    Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial.
    Levin FR; Mariani JJ; Specker S; Mooney M; Mahony A; Brooks DJ; Babb D; Bai Y; Eberly LE; Nunes EV; Grabowski J
    JAMA Psychiatry; 2015 Jun; 72(6):593-602. PubMed ID: 25887096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced inattention and hyperactivity and improved cognition after marine oil extract (PCSO-524®) supplementation in children and adolescents with clinical and subclinical symptoms of attention-deficit hyperactivity disorder (ADHD): a randomised, double-blind, placebo-controlled trial.
    Kean JD; Sarris J; Scholey A; Silberstein R; Downey LA; Stough C
    Psychopharmacology (Berl); 2017 Feb; 234(3):403-420. PubMed ID: 27921139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial.
    Stein MA; Sikirica V; Weiss MD; Robertson B; Lyne A; Newcorn JH
    CNS Drugs; 2015 Nov; 29(11):953-62. PubMed ID: 26547425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated Database.
    De Bruyckere K; Bushe C; Bartel C; Berggren L; Kan CC; Dittmann RW
    CNS Drugs; 2016 Jun; 30(6):541-58. PubMed ID: 27224994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protocol investigating the clinical utility of an objective measure of attention, impulsivity and activity (QbTest) for optimising medication management in children and young people with ADHD 'QbTest Utility for Optimising Treatment in ADHD' (QUOTA): a feasibility randomised controlled trial.
    Hall CL; James M; Brown S; Martin JL; Brown N; Selby K; Clarke J; Vijayan H; Guo B; Sayal K; Hollis C; Groom MJ
    BMJ Open; 2018 Feb; 8(2):e021104. PubMed ID: 29453304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder.
    Paterson R; Douglas C; Hallmayer J; Hagan M; Krupenia Z
    Aust N Z J Psychiatry; 1999 Aug; 33(4):494-502. PubMed ID: 10483843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive-behavioural therapy in medication-treated adults with attention-deficit/hyperactivity disorder and co-morbid psychopathology: a randomized controlled trial using multi-level analysis.
    Young S; Khondoker M; Emilsson B; Sigurdsson JF; Philipp-Wiegmann F; Baldursson G; Olafsdottir H; Gudjonsson G
    Psychol Med; 2015 Oct; 45(13):2793-804. PubMed ID: 26022103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AZD3480, a novel nicotinic receptor agonist, for the treatment of attention-deficit/hyperactivity disorder in adults.
    Potter AS; Dunbar G; Mazzulla E; Hosford D; Newhouse PA
    Biol Psychiatry; 2014 Feb; 75(3):207-14. PubMed ID: 23856296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin-mineral treatment of attention-deficit hyperactivity disorder in adults: double-blind randomised placebo-controlled trial.
    Rucklidge JJ; Frampton CM; Gorman B; Boggis A
    Br J Psychiatry; 2014; 204():306-15. PubMed ID: 24482441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder.
    Wilens TE; Biederman J; Prince J; Spencer TJ; Faraone SV; Warburton R; Schleifer D; Harding M; Linehan C; Geller D
    Am J Psychiatry; 1996 Sep; 153(9):1147-53. PubMed ID: 8780417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
    CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder.
    Bilici M; Yildirim F; Kandil S; Bekaroğlu M; Yildirmiş S; Değer O; Ulgen M; Yildiran A; Aksu H
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):181-90. PubMed ID: 14687872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.